Join
Live feed
·
PRReleasevia Quantisnow
Protalix BioTherapeutics Inc. (DE) logo

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

ByQuantisnow·Wall Street's wire, on your screen.
PLX· Protalix BioTherapeutics Inc. (DE)
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PLX (Protalix BioTherapeutics Inc. (DE)) and more on Quantisnow.